VÍTOVEC, Jiří, Jindřich ŠPINAR a Lenka ŠPINAROVÁ. Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan. Interni Medicina pro Praxi. SOLEN s.r.o., 2019, roč. 21, č. 2, s. 118 - 124. ISSN 1212-7299. Dostupné z: https://dx.doi.org/10.36290/int.2019.044. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1726980, author = {Vítovec, Jiří and Špinar, Jindřich and Špinarová, Lenka}, article_number = {2}, doi = {http://dx.doi.org/10.36290/int.2019.044}, keywords = {Dual inhibition; Heart failure; Sacubitril-valsartan}, language = {cze}, issn = {1212-7299}, journal = {Interni Medicina pro Praxi}, title = {Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan}, url = {https://www.internimedicina.cz/pdfs/int/2019/02/11.pdf}, volume = {21}, year = {2019} }
TY - JOUR ID - 1726980 AU - Vítovec, Jiří - Špinar, Jindřich - Špinarová, Lenka PY - 2019 TI - Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan JF - Interni Medicina pro Praxi VL - 21 IS - 2 SP - 118 - 124 EP - 118 - 124 PB - SOLEN s.r.o. SN - 12127299 KW - Dual inhibition KW - Heart failure KW - Sacubitril-valsartan UR - https://www.internimedicina.cz/pdfs/int/2019/02/11.pdf N2 - Dual antagonist of AT1 receptors for angiotensin II (ARB) and neprilysin, generic name sacubitril valsartan (formaly LCZ 696 or angiotensin receptor blocker and neprilysin inhibitor - ARNI) was clinicaly tested in the treatmet of hypertension and heart failure. The mechanism of action is in the blockade of AT1 receptros by valsartan in combination with decreased degradation of natriuretic peptides with increased vasodilatation. The first clinical trial PARAMOUNT with LCZ696 in the treatment of Heart failure patients with preserved ejection fraction has whown significant decrea-se of NT-proBNP concentrations. Clinical trial PARADIGM-HF in patients with decreased ejection fraction and high natriuretic peptides levels was fi-nished prematuraly for a positive effect of LCZ696 both on mortality and morbidity if compared with enalapril. Cardiovascular mortality was decreased by 20%, first hospitalisation for Heart failure by 21%. The PARAGON-HF study is testing the effect of sacubitril valsartan in patients with preserved ejection fraction ER -
VÍTOVEC, Jiří, Jindřich ŠPINAR a Lenka ŠPINAROVÁ. Duální inhibice AT1 receptoru pro angiotenzin II~a~neprilysinu aneb sacubitril-valsartan. \textit{Interni Medicina pro Praxi}. SOLEN s.r.o., 2019, roč.~21, č.~2, s.~118 - 124. ISSN~1212-7299. Dostupné z: https://dx.doi.org/10.36290/int.2019.044.
|